[Experience with fenazid in perperas with respiratory tuberculosis and post-tuberculous changes in the lung].
The paper describes the authors' experience with the new Russian antituberculous agent isonicotinic acid hydrazide (INAH) used in postpartum female patients with different forms of active and inactive pulmonary tuberculosis. The study group comprised 20 puerperas with respiratory tuberculosis of different degrees who received fenazid in a dose of 0.5 g daily for 2-3 months for therapeutic and preventive purposes. The comparison group included 36 puerperas given isoniazid in a daily dose of 0.6 g. The effectiveness of fenazid in treating and preventing respiratory tuberculosis allowed the agent to be used in postpartum period and recommended if there are side effects of isoniazid and altered peripheral blood parameters.
Stakhanov
V A
VA
Makarov
O V
OV
Kaiukova
S I
SI
Chernousova
L N
LN
Borisova
M I
MI
Slastnikova
E B
EB
D000328:Adult; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D008168:Lung / Q000473:pathology*; D049590:Postpartum Period; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology
D006454:Hemoglobins; D007538:Isoniazid